Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Phase 2 Obesity Trial Results (Jastreboff et al., 2023) The landmark Phase 2 trial enrolled 338 adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
Application Recommendation Take 1 capsule 3 times a day unchewed with sufficient liquid
Recent Developments: As of mid-2026, the FDA has proposed to exclude popular GLP-1 substances like Semaglutide, Tirzepatide, and Liraglutide from the list, concluding that there is no clinical need to compound them from bulk ingredients when approved versions are available
Other findings include: About eight in ten (82%) adults say they have heard at least a little about these drugs, including about three in ten (32%) who say they have heard a lot about them
US$ 20.35
US$ 27.17
US$ 28.09
